New leadership appointments at IFPMA

pharmafield logo - pharma news

 he International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has appointed Haruo Naito as President and Eduardo Pisani as Director General.

Naito’s predecessor, Fred Hassan, Chairman and CEO of Schering-Plough, stepped down as IFPMA President on the completion of his company’s merger with Merck & Co.

Naito was re-elected as Vice President of the IFPMA in November 2008, at which time David Brennan, CEO of AstraZeneca, was elected as the other Vice President.

The IFPMA Vice President’s position vacated by Naito will be filled by Lamberto Andreotti, President and CEO of Bristol-Myers Squibb.

Mr Naito said: “As IFPMA President since 2006, Mr. Hassan has provided wise leadership in difficult times and it is an honor to be asked to succeed him. He has encouraged the IFPMA to engage more with other stakeholders, especially those in developing countries, and we can build on the outreach initiated under his presidency.

“The value of this interactive approach is exemplified by our ongoing collaboration with the WHO and others to deliver a rapid and effective response to the threat of an H1N1 influenza pandemic.”

Eduardo Pisani will take office from January 2010 and will succeed Michael D. Boyd, who has been serving as Acting Director General since April this year.

Mr Naito added: “Mr. Pisani is well-equipped to lead the IFPMA Secretariat, as he has 20 years of professional experience in the healthcare sector and has worked on public policy and legal affairs for a number of companies, while also contributing to the activities of several IFPMA committees. He is a respected figure within our industry, with a deep understanding of many of the international issues covered by the IFPMA. I am sure that he will prove an excellent ambassador for our industry, helping to strengthen our dialog with different stakeholders in Geneva and elsewhere.”

Pisani comes to the IFPMA from his position as Vice-President, International Policy and Government Affairs, at Bristol-Myers Squibb, a company he joined in 2001.

During his time at BMS, Pisani contributed to the development of policy initiatives at European level in major disease areas like infectious diseases and mental health, as well as to industry work on the value of medicines.

Prior to that, Pisani held positions as legal counsel at Immuno AG in Belgium and Austria, at Baxter Healthcare in Belgium and Italy, and in Eur opean Policy and Government Affairs at Adamson Associates and SmithKline Beecham in Belgium.

The IFPMA’s mission is to serve as the industry’s interface with the WHO, WTO, WIPO and other United Nations’ bodies, both in Geneva and elsewhere.